Multidisciplinary Care Program to Secure mEdication Therapy for hematoLOgy Patients Receiving Injectable Anticancer Drugs

Completed

• Conditions: G-CHOP Chemotherapy; R-CHOP Chemotherapy; Chemotherapy Effect
• Interventions: Other: Assessment of patient satisfaction regarding tele-consultation; Other: Literacy questionnaire; Other: Collection of socio-demographic characteristics; Other: Assessment of patient knowledge on chemotherapy side effects and support medications; Other: Assessment of patient satisfaction on pharmaceutical follow-up

• Registration Number: NCT05350930
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Several experiences of multidisciplinary care pathways associating oncologists, pharmacists and nurses have been reported for cancer patients, with positive results on medication management safety, reduction of Drug-Related Problems (DRPs), and re-hospitalizations.

This study aims to evaluate the impact of a multidisciplinary city-hospital follow-up program on medication management safety in haematological oncology patients receiving intravenous chemotherapy in onco-haematology. Additional aspects will be evaluated, such as the impact of the follow-up on the city-hospital link, satisfaction of patients and professionals involved in the follow-up and the use of telecare

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2022-04-22
• Study First Submitted QC: 2022-04-22
• Study First Posted: 2022-04-28
• Study Start: 2022-06-09
• Primary Completion: 2023-02-15
• Study Completion: 2023-02-15
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-18
• Last Update Posted: 2023-12-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

Adult patients aged 18 years or older With hematological malignancy at any stage Initiating R-CHOP or G-CHOP chemotherapy Who do not object to participation in the study and use of collected data

Read More

Exclusion Criteria

• Patients already enrolled in a clinical trial evaluating any drug product

• Patients living in an institution

• Patients protected by law

  • Adults subject to a legal protection measure (curatorship, guardianship) (article L1121-8 of the CSP)
  • Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and persons admitted to a health or social establishment (article L1121-6 of the CSP)

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
R-CHOP or G-CHOP chemotherapy	Assessment of patient satisfaction regarding tele-consultation	Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy
R-CHOP or G-CHOP chemotherapy	Assessment of patient knowledge on chemotherapy side effects and support medications	Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy
R-CHOP or G-CHOP chemotherapy	Collection of socio-demographic characteristics	Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy
R-CHOP or G-CHOP chemotherapy	Literacy questionnaire	Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy
R-CHOP or G-CHOP chemotherapy	Assessment of patient satisfaction on pharmaceutical follow-up	Patients with hematological malignancies receiving R-CHOP or G-CHOP chemotherapy

Primary Outcome Measures

Name	Time	Method
Evaluation of the clinical impact of pharmacist interventions at first cycle of chemotherapy, according to the CLEO© scale.	6 months after inclusion	Each pharmacist intervention performed during patient follow-up will be rated according to its expected level of clinic impact (major, moderate, minor, null)

Trial Locations

Locations (1)

Hôpital Lyon Sud - Hospices Civils de lyon; 🇫🇷 Pierre-Bénite, France